226 related articles for article (PubMed ID: 33355298)
21. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
22. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
23. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
25. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
26. Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
Li Y; Zhang N; Zhang L; Song Y; Liu J; Yu J; Yang M
Carcinogenesis; 2020 Sep; 41(9):1195-1202. PubMed ID: 32815538
[TBL] [Abstract][Full Text] [Related]
27. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
28. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
29. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
[TBL] [Abstract][Full Text] [Related]
31. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
[TBL] [Abstract][Full Text] [Related]
32. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
33. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
[TBL] [Abstract][Full Text] [Related]
34. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
35. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
36. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
37. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
38. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
39. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
40. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]